![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
GW Pharm. | LSE:GWP | London | Ordinary Share | GB0030544687 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 735.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMGWP RNS Number : 8861N GW Pharmaceuticals PLC 18 June 2010 GW Pharmaceuticals plc ("GW" or "the Group") Product Update Porton Down, UK, 18 June 2010: Consistent with previous guidance that a UK approval for Sativex is expected by the end of Q2 2010, GW confirms that it has just received formal notification of the grant of a product licence from MHRA for Sativex. GW's marketing partner, Bayer Schering Pharma, will be announcing the formal UK launch of Sativex on Monday 21 June and further details will be provided at that time. Enquiries: +----------------------------------------+--------------------------+ | Financial Dynamics | + 44 20 7831 3113 | +----------------------------------------+--------------------------+ | Ben Atwell / John Dineen | | +----------------------------------------+--------------------------+ | | | +----------------------------------------+--------------------------+ | Piper Jaffray Ltd | +44 (0)20 3142 8700 | +----------------------------------------+--------------------------+ | Neil Mackison / Rupert Winckler | | +----------------------------------------+--------------------------+ Notes to Editors About GW GW was founded in 1998 and listed on the AiM, a market of the London Stock Exchange, in June 2001. Operating under license from the UK Home Office, the company researches and develops cannabinoid pharmaceutical products for patients who suffer from a range of serious ailments, in particular multiple sclerosis and cancer pain. GW has assembled a large in-house scientific team with expertise in cannabinoid science as well as experience in the development of both plant-based prescription pharmaceutical products and medicines containing controlled substances. GW occupies a world leading position in cannabinoids and has developed an extensive international network of the most prominent scientists in the field. This news release may contain forward-looking statements that reflect GWs current expectations regarding future events, including development and regulatory clearance of the GW's products. Forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors, including (inter alia), the success of the GW's research strategies, the applicability of the discoveries made therein, the successful and timely completion of uncertainties related to the regulatory process, and the acceptance of Sativex and other products by consumer and medical professionals. This information is provided by RNS The company news service from the London Stock Exchange END MSCKKFDNNBKDDAD
1 Year Gw Pharmaceuticals Chart |
1 Month Gw Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions